Compare Amgen, Inc. (AMGN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Wells Fargo & Co — how do they compare? Amgen, Inc. trades at $356.51 (market cap $196.12B), while Wells Fargo & Co trades at $86.61 (market cap $266.73B). The key difference: Wells Fargo & Co is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | WFC | |
|---|---|---|
Market Cap | $196.12B | $266.73B |
Sector | Health | Financials |
52-Week High | $388.16 | $96.40 |
52-Week Low | $271.18 | $73.42 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Wells Fargo (WFC) trades at $87.12, up 0.24% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows steady revenue growth to $83.70B in 2025 and net income of $21.34B, with a P/E of 13.47 suggesting reasonable valuation. Recent news highlights anticipation for Q2 2026 earnings on July 14, 2026, with analysts expecting EPS of $1.73. The dividend of $0.45 per share was paid in June 2026, supporting income investors.
Outlook is cautiously optimistic with a consensus price target of $99.44, implying 14% upside, though risks include volatile cash flows and regulatory scrutiny. Earnings misses in recent quarters warrant monitoring, but improving net interest income and fee growth could drive positive surprises. Investor sentiment is balanced with 45% buy ratings, but macroeconomic pressures on banks remain a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
